Translating Stem Cell Studies to the Clinic for CNS Repair: Current State of the Art and the Need for a Rosetta Stone
Translating Stem Cell Studies to the Clinic for CNS Repair: Current State of the Art and the Need for a Rosetta Stone
复制标题
DOI：
10.1016/j.neuron.2011.05.007
复制
发表时间：
2011-05-26
期刊：
影响因子：
16.2
通讯作者：
Temple, Sally
中科院分区：
文献类型：
--
作者：
Aboody, Karen;Capela, Alexandra;Temple, Sally
自从二十年前发现神经干细胞（NSC）并在十年后进行前瞻性分离以来，神经干细胞（NSC）、它们的祖细胞和分化的细胞衍生物沿着其他基于干细胞的策略已经稳步地向临床试验发展，这是由寻找用于中枢神经系统（CNS）疾病和损伤的修复疗法的巨大需求所刺激的。目前在CNS中使用干细胞的I/II期试验是广泛预期的下一代再生疗法的先锋，因此是干细胞治疗过程的先驱。虽然翻译通常是行业的权限，但学术研究人员越来越倾向于将他们的发现用于治疗，并面临知识差距和资源获取方面的挑战，这些挑战因细胞治疗独特的财务，制造，科学和监管方面而加剧。设想的解决方案，既解决重大未满足的医疗需求，并导致增加基础和转化研究的资金。
Since their discovery twenty years ago and prospective isolation a decade later, neural stem cells (NSCs), their progenitors, and differentiated cell derivatives along with other stem-cell based strategies have advanced steadily toward clinical trials, spurred by the immense need to find reparative therapeutics for central nervous system (CNS) diseases and injury. Current phase I/II trials using stem cells in the CNS are the vanguard for the widely anticipated next generation of regenerative therapies and as such are pioneering the stem cell therapy process. While translation has typically been the purview of industry, academic researchers are increasingly driven to bring their findings toward treatments and face challenges in knowledge gap and resource access that are accentuated by the unique financial, manufacturing, scientific, and regulatory aspects of cell therapy. Solutions are envisioned that both address the significant unmet medical need and lead to increased funding for basic and translational research.